article thumbnail

MyMD Pharmaceuticals Announces New Data from Comparative Study on Lead Compound MYMD-1

Cannabis Law Report

New data shows MYMD-1 has key differentiators and capabilities compared to existing TNF inhibitor drugs. Data also demonstrated that none of the biological drugs selected for the comparison study proved to be anti-proliferative to any of the primary cell types assessed. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc.

article thumbnail

Growers in the Emerald Triangle are Facing a Potential Extinction Event |

SpeedWeed

“This is an extinction event,” Johnny Casali, owner of Huckleberry Hill Farms , a cannabis farm in southern Humboldt County, said over the phone. Casali is referring to a recent wholesale price collapse in California’s outdoor-grown cannabis market. . Data firms like Leaflink have not yet registered a price drop.

Events 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Clinical Trial on Alzheimer’s Patients Indicates Positive Safety and Tolerability Data for IGC’s THC-Based Investigational New Drug

Cannabis Law Report

(“IGC” or the “Company”) today announced positive primary endpoint data for its Phase 1 clinical trial for IGC-AD1, which is a proprietary cannabinoid-based investigational new drug candidate for patients who have Alzheimer’s disease. Safety and Tolerability (S&T) was assessed by asking participants to record Adverse Events (AEs).

article thumbnail

RYAH Group Ships Devices for Use in Pilot Program with Medicann in Jersey, Channel Islands

Cannabis Law Report

RYAH is pleased to contribute RYAH’s IoT devices and data platform and work with Medicann toward perfecting prescribing practices and dosing regimens,” said Gregory Wagner , CEO of RYAH Group, Inc. With a strong IP portfolio, RYAH gathers deep and insightful data on the complete patient session and formulation life cycle.

Programs 100
article thumbnail

RYAH Medtech Inc. Completes Initial Shipment for Major UK-based Clinical Trial

Cannabis Law Report

Given the size and scale of the study, RYAH has developed a custom software solution, using OAuth API-integration to protect the privacy of the participants in the study, with the goal of enabling a fully integrated, patient feedback and data collection capability. About RYAH Group, Inc. RYAH Group, Inc.

article thumbnail

RYAH Group Partners with the University of Milan to Develop Conversion Measurement Standards for Dry Herb Inhalation Therapies

Cannabis Law Report

The data from the study is expected to be embedded into the RYAH MD platform, with the goal of enabling healthcare professionals to administer THC, CBD and terpenes in milliliters, which are then expected to automatically be converted into milligrams to allow for a customized, targeted patient inhalation session. “Our billion by 2027.

Therapy 76
article thumbnail

Report: Efficacy and safety of medical cannabinoids in children: a systematic review and meta-analysis

Cannabis Law Report

While cannabidiol was associated with a reduction in reported seizure events (RR?=?0.59, A qualitative assessment suggests that medical cannabinoids might be associated with adverse mental events. Adverse mental events were reported as well, however, more research should be performed to assess well this outcome. 1.69, 95% CI [1.20–2.36])

Safety 52